Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/Theravance Target 2008 Phase III Start For Next-Gen Bronchodilators

This article was originally published in The Pink Sheet Daily

Executive Summary

Two compounds stemming from the collaboration given once daily were equivalent to salmeterol twice daily in Phase IIb clinical studies.

You may also be interested in...



Theravance Trims Loss, CEO “Optimistic” About FDA Panel Ahead

Feb. 27 brings first test of noninferiority’s importance to regulators, analyst tells “The Pink Sheet” DAILY.

Theravance Trims Loss, CEO “Optimistic” About FDA Panel Ahead

Feb. 27 brings first test of noninferiority’s importance to regulators, analyst tells “The Pink Sheet” DAILY.

Dey Perforomist Inhalation Solution Clears FDA for Bronchoconstriction In COPD

Approval marks the first FDA-approved nebulizer formulation of formoterol.

Related Content

Topics

UsernamePublicRestriction

Register

LL1130421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel